MYCN and neuroblastoma: MYCN-amplification in neuroblastoma elevates fatty acid uptake, exposing a metabolic vulnerability that can be exploited by targeting FATP2, a fatty acid transport protein regulated by MYCN whose inhibition supresses tumour growth in vivo [47].